Semaglutide 2.4 mg Dominates Resmetirom in MASH Cost-Effectiveness Model
This industry-funded pharmacoeconomic model gives Gastroenterology and Hepatology pharmacists a payer-perspective comparison of the two FDA-approved MASH pharmacotherapies against standard of care.
Semaglutide 2.4 mg offers cost-effective treatment for MASH.
Non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis has significant clinical and economic impacts, necessitating effective treatments. Semaglutide 2.4 mg increased quality-adjusted life years (QALYs) by 1.66 with an incremental cost of US$33,031, presenting the most favorable cost-effectiveness profile. Semaglutide 2.4 mg is likely cost-effective at standard willingness-to-pay thresholds, suggesting it could be a preferred treatment in clinical practice for MASH. Semaglutide 2.4 mg offers cost-effective treatment for MASH with favorable outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:McGovern AJ, Cinfio F, Luo R A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. PharmacoEconomics. 2026. doi:10.1007/s40273-026-01647-8
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.